The Reproductive Care of Women Living With Hepatitis C Infection
VIII. Care of Pregnant Women Living with HCV
A. Preconception Care
Ideally prenatal care should begin at a preconception
consultation with a physician knowledgeable in the management of
hepatitis C or infectious diseases in pregnancy. It should involve
a discussion of the natural history of the disease, implications
for the pregnancy, consequences for the fetus, risk of vertical
transmission, therapies, and risk reduction behaviours. Possible
routes of infection should be discussed in a non-judgmental, sensitive
fashion after having established rapport with the patient.
As in all preconception visits, a complete medical
history and physical examination should be performed, but with particular
reference to issues of importance to hepatitis C, including:
- Current medical history: diagnosis, stage, and course of disease,
presence of complications
- Past medical history: other liver conditions
- Past obstetric history: transfusions, cholestasis, HELLP
- Drug history:
- prescription medication that may be potentially hepatotoxic
(see Section VII.D: Principles of prescribing in HCV
infected women)
- interferon and ribavirin therapy
- non-prescription medication - acetaminophen
- drug abuse - whether the patient has ever injected
drugs
- Alcohol history: it is important to emphasize the negative effect
of alcohol on the course of disease. Consumption above two units
per day accelerates the progression of HCV infection and abstinence
represents the best option for all women.
- Liver function: current test results should be obtained and
reviewed with the woman.
- immunity to hepatitis A and B should be determined and immunization
offered as appropriate.
- Given that transmission may be related to the presence of circulating
HCV RNA, a recent qualitative test may be of use in this discussion.
If HCV RNA is negative, then the vertical transmission rate would
appear to be decreased almost to zero. Quantitative tests are
not yet validated for predicting individual risk. In view of the
sophistication of these tests, their interpretation should probably
be discussed with a specialist.
- lCombined therapy must have been completed for at least six
months before embarking on pregnancy.115 The teratogenicity
of ribavirin is well documented and inadvertent exposure should
result in counselling regarding options. Pregnancy termination
is an option to be considered. Information to help the patient
receiving interferon consider options remains sparse.116-119
B. Prenatal Care
Women aware of their HCV positive status should
consult their physician early during the course of pregnancy for
comprehensive prenatal care. Early assessment of both general physical
health and liver function will identify those patients most likely
to benefit from a multi-disciplinary team approach. As only about
30 percent of the HCV infected population is aware of the diagnosis,
early pregnancy is also an opportune time to identify further cases
through risk assessment and targeted screening tests, as previously
discussed.
1. General points with consideration given to the following points:
- It is worthwhile to continue to seek risk factors at initial
and subsequent prenatal visits as previously discussed. Anti-HCV
antibodies are not protective and the acquisition of different
strains can and does occur, making the implementation of risk
reduction strategies worthwhile.120
- Frequency of visits should be determined on an individual basis
according to the medical and obstetric condition of the patient.
- Patients should refrain from consuming alcohol.
- It may be wise to avoid the use of drugs which are potentially
hepatotoxic or require extensive metabolism in the liver during
the pregnancy.
2. Laboratory investigations
In addition to routine prenatal laboratory investigations,
the following specific tests should be requested in a patient with
HCV in early pregnancy:
- Liver function tests, aminotransferases
- Albumin
- Bilirubin
- INR
- Anti-HBs
- Anti-HA total or IgG
- HCV RNA qualitative test
3. Monitoring the pregnancy
- Liver function including transaminases should be measured in
each trimester. Baseline values will be useful to distinguish
between HCV related liver dysfunction and that from pregnancy
induced complications such as gestational hypertension/
HELLP syndrome or cholestasis of pregnancy.121-123
- There is no report of an increase in incidence of preterm labour,
IUGR or fetal distress in the pregnancies of women with HCV in
the absence of other contributing factors.14,31Consequently,
no specific recommendations can be made for fetal assessment during
pregnancy.
4. Ultrasound diagnosis
Indications for diagnostic ultrasound evaluation
will not differ from that of the general pregnant population, as
no association between HCV and fetal dysmorphism has been made.
5. Invasive procedures
There is no data regarding procedures such as
amniocentesis, fetal blood sampling, or chorionic villous biopsy,
and the risk of vertical transmission.124 It is the view
of the panel that women with undetectable HCV RNA by qualitative
PCR may not carry an increased risk of vertical transmission following
these procedures. In the presence of HCV RNA, the indication and
risk of abnormality must be balanced against the potential increase
in transmission risk. The risk of maternal fetal haemorrhage during
amniocentesis is approximately ten percent.
C. Intrapartum Management
1. Mode of delivery
Even though a few retrospective studies have suggested
a lower transmission rate after Caesarean section, the evidence
is not conclusive to recommend it as a protective intervention.
Women with HCV should therefore be allowed to deliver vaginally
unless obstetric reasons dictate otherwise. As in all labours, universal
precautions should be observed. There is no need to isolate either
mother or infant.
2. Induction of labour
HCV infection is not an indication for induction
of labour. Labour should be allowed to begin spontaneously in the
absence of other indications. Similarly, augmentation should be
performed according to local practices.
Although there is no data regarding the duration of membrane rupture
and vertical transmission rates, it would seem sensible to maintain
membrane integrity as long as possible to avoid fetal exposure to
potentially infected cervico-vaginal secretions. Similarly, episiotomy
should require careful consideration.
3. Intrapartum fetal assessment
Intrapartum fetal assessment should follow the
clinical guidelines established by the SOGC.125 Intermittent
auscultation or external monitoring is to be preferred, although
no case of fetal infection has been linked to the use of a scalp
electrode. However, as internal monitoring, including scalp pH measurement,
constitutes a skin breaking procedure, it should be used only if
deemed absolutely necessary for the assessment of fetal well-being.
D. Postpartum Management
1. General points
Basic hygiene and the disposal of potentially
infected material should be discussed with the patient.
2. Breastfeeding
HCV RNA and anti-HCV antibodies have been detected
in colostrum and breast milk. However, in multiple series no case
of transmission through breastfeeding has been documented. It is
generally felt that breastfeeding is not contraindicated.36,62
3. Contraception
Effective future contraception should be discussed
as part of obstetrical care. For further discussion please see Section
V. B. 3b: Contraception.
E. Care of the Newborn
1. General care
Infants may be cared for according to usual hospital
procedure while universal precautions are practiced. There is no
need for the mother to alter normal child care routines and the
use of gloves, masks or extra sterilization is unnecessary. HCV
is a bloodborne pathogen and is not transmitted by urine or stools.
2. Infant testing
As passive transfer of maternal antibodies (IgG)
occurs transplacentally, all infants of mothers with HCV will be
positive for anti-HCV at birth. Uninfected infants should usually
have cleared these antibodies by 12 to 15 months of age. The higher
the level in the mother, the longer they will take to clear. Earlier
verification of infection status is possible, usually starting at
two to three months of age, and relies on the identification of
circulating HCV RNA by qualitative PCR. It should be remembered
that early diagnosis is unlikely to alter the course of events,
as the disease in children tends to follow a benign course and therapy
is not indicated. However, a negative test may serve to alleviate
parental anxiety.
3. Infant immunization
In addition to routine immunizations, immunization
for hepatitis B should be ommenced in the postnatal period. If the
mother is HBsAg positive, appropriate active and passive immunoprophylaxis
should be given in the form of hepatitis B immunoglobulin and hepatitis
B vaccine. Vaccination against hepatitis A should be given at about
one year of age.
A paediatric or infectious diseases consultation is advised to deal
with the specific issues regarding testing and immunization.126
Back
|